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Abstract
Background: Although some studies show higher antiretroviral concentrations in women compared to men, data
are limited. We conducted a cross-sectional study of HIV-positive women to determine if protease inhibitor (PI) and
non-nucleoside reverse transcriptase inhibitor (NNRTI) Cmin and Cmax values were significantly different than
historical general population (predominantly male) averages and to evaluate correlates of higher concentrations.
Methods: HIV-positive women with virologic suppression (viral load < 50copies/mL) on their first antiretroviral
regimen were enrolled. Timed blood samples for Cmin and Cmax were drawn weekly for 3 weeks. The ratio of each
individual’s median Cmin and Cmax to the published population mean values for their PI or NNRTI was calculated
and assessed using Wilcoxon sign-rank. Intra- and inter-patient variability of antiretroviral drug levels was assessed
using coefficient of variation and intra-class correlation. Linear regression was used to identify correlates of the
square root-transformed Cmin and Cmax ratios.
Results: Data from 82 women were analyzed. Their median age was 41 years (IQR=36-48) and duration of
antiretrovirals was 20 months (IQR=9-45). Median antiretroviral Cmin and Cmax ratios were 1.21 (IQR=0.72-1.89,
p=0.003) (highest ratios for nevirapine and lopinavir) and 0.82 (IQR=0.59-1.14, p=0.004), respectively. Nevirapine and
efavirenz showed the least and unboosted atazanavir showed the most intra- and inter-patient variability. Higher
CD4+ count correlated with higher Cmin. No significant correlates for Cmax were found.
Conclusions: Compared to historical control data, Cmin in the women enrolled was significantly higher whereas
Cmax was significantly lower. Antiretroviral Cmin ratios were highly variable within and between participants. There
were no clinically relevant correlates of drug concentrations.
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Background
Since the advent of combination antiretroviral therapy
(cART), there has been a dramatic decrease in the mor-
tality of individuals infected with human immunodefi-
ciency virus (HIV) [1]. Traditionally, this combination
has included two drugs from the antiretroviral class of
nucleoside reverse transcriptase inhibitors (NRTIs) and
either one from the class of protease inhibitors (PIs) or
one from the class of non-nucleoside reverse transcript-
ase inhibitors (NNRTIs) [2]. If the third agent is from
the PI class, it is often combined with a low dose of rito-
navir in order to boost its drug levels [2]. More recently,
raltegavir has been added as an option for the third
agent, but remains rarely used in Canada due to cost [3].
Despite these tremendous advances in HIV manage-
ment, there remain several important complications re-
lated to antiretroviral drug use, one of the most notable
being drug-related adverse events (AEs) and toxicities [4],
which can negatively impact patients’ quality of life, con-
tributing to non-adherence and drug resistance and ultim-
ately effectiveness. Adverse drug reactions to antiret-
rovirals are a major reason for discontinuing or changing
therapy [5,6]. Furthermore, these drug-related complica-
tions can significantly contribute to morbidity, hospitaliza-
tions, and mortality in this population [7-10].
Women constitute one of the fastest-rising population
groups at risk for infection with HIV, representing over
50% of cases worldwide, and approximately 25% of new
cases in the United States (U.S.) and 28% of new cases
in Canada [1-3]. Surprisingly, little is known about the
differential efficacy and toxicity of various antiretroviral
drugs in women compared to men [11]. This gap in
knowledge is a result of the initial exclusion and contin-
ued underrepresentation of women in antiretroviral clin-
ical trials [12]. This circumstance has slowly started to
change, and there are now more longitudinal studies
examining women-specific issues [13,14]. Many studies
in the general population have shown that AEs are more
common in women than in men [15]. In the HIV-
infected population, higher incidence rates of increased
systemic symptoms (such as nausea, vomiting and diar-
rhea), as well as organ toxicity (including anemia, hep-
atotoxicity, pancreatitis, lactic acidosis, peripheral
neuropathy, and notable lipodystrophy), have been ob-
served in women compared to men [11,16,17]. For nevi-
rapine, female gender and higher CD4+ cell counts were
risk factors for fatal hepatitis, and this observation has
led regulatory authorities to release warnings on its use
in certain female populations [18].
Most of these studies assessing sex differences in anti-
retroviral AEs rates are limited in that they only identify
the issue of increased toxicity in women and do not try to
elucidate the cause or management [16,19,20]. The poten-
tial causes of these gender differences in antiretroviral
toxicities may have a sound biologic basis possibly related
to differences in physiology and/or the influence of sex
hormones on drug metabolism. All aspects of drug hand-
ling and exposure may be different in women versus men,
including bioavailability (with lower gastric emptying time
due to hormonal contraception use or pregnancy) and dis-
tribution (lower body weight, smaller organ size, higher
body fat content, altered gastric motility, greater organ
blood flow, and altered protein binding secondary to en-
dogenous or exogenous estrogens). Metabolism and elim-
ination of drugs have also exhibited gender differences
related to differences in expression and activity of various
drug transporters and metabolizing enzymes [20,21]. Of
particular interest, a better understanding of antiretroviral
pharmacokinetics (PK) in women and how these drug
levels impact AEs and toxicities in women is crucial, and
will lead to more effective methods of treatment, reduced
discomfort, possible enhanced adherence and improved
morbidity and/or mortality.
Although a few investigations have considered PK differ-
ences that occur between men and women, most of these
studies involved the use of older antiretroviral agents and
were assessed in small sample sizes [21-29]. Furthermore,
a number of potentially confounding variables such as
race, age, weight, menstruation, and hepatitis co-infection
have not been explored as determinants impacting drug
levels in a female population. We conducted a cross-
sectional study of HIV-positive women taking their first
combination ART to determine if drug levels (Cmin and
Cmax) of currently used PIs and NNRTIs were significantly
higher in this population as compared to the historical
general (predominantly male) population and to evaluate
correlates of higher concentrations.
Methods
Ethics statement
The study was reviewed and received ethics approval by
the Full Institutional Research Ethics Board (REB) of
main coordinating research centre, Women’s College Re-
search Institute, Toronto, Canada (REB# 2006–003).
Additional Full Institutional REB approval was obtained
from each research site prior to commencement. All
study personnel were trained in and practiced under the
principles of the Declaration of Helsinki. All study can-
didates were informed about this study and written in-
formed consent was obtained from every participant
prior enrollment.
Study population
We carried out a cross-sectional study with participants
who met the following inclusion criteria: 1) HIV-positive,
2) biologically female, 3) 18 years of age or older, 4)
taking their first cART regimen containing either a PI or
an NNRTI with a backbone of NRTI as per common
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practice for at least 3 months (but could have had prior
switches that were not due to virologic failure), 5) taking
either a PI or an NNRTI but not both, 6) if taking a PI,
must have been taking only one PI excluding low dose ri-
tonavir used as boosting and 7) had evidence of full viro-
logic suppression (HIV-1 RNA VL < 50 copies/mL) on at
least two occasions at least one month apart. The patient
population was limited to women who were on their first
cART regimen in order to ensure a more homogeneous
population. The current analysis was limited to candidates
who were taking the following antiretroviral drugs
(atazanavir, atazanavir boosted with ritonavir, lopinavir
boosted with ritonavir, efavirenz and nevirapine) [3,30].
Participants could not take both a PI and NNRTI or two
PIs excluding ritonavir as there are multiple drug interac-
tions between these agents which would lead to uninter-
pretable results. Further, participating women had to have
full virologic suppression to avoid inclusion of women
who experience difficulty with drug adherence. The 3
month requirement for being on a cART regimen was
mandated to 1) ensure stabilization of adherence as there
may be an adjustment period as patients get accustomed
to taking their new drug regimen, 2) eliminate early dis-
continuations due to drug toxicities which often happen
during the first 3 months of therapy, and to a lesser extend
3) to ensure drug steady state as there is some variation
between drugs [5].
A planned sample size of 80 was calculated in order to
estimate if the mean ratio of the Cmin values to historical
values for the general population was significantly differ-
ent from 1.0, assuming an alternative hypothesis of 1.2
with a standard deviation of 0.64, 80% power and a sig-
nificance level of 0.05. Recruitment was conducted from
February, 2007 to November, 2008 from 14 primary care
and specialty HIV clinics from across Canada. Recruit-
ment and study qualification determination was carried
out by the site investigator and research staff. The re-
cruitment was carried out in a non-random consecutive
manner as research staff were instructed to invite every
consecutive qualifying woman who received services in
their clinic on all days that care was provided.
Data collection
Study visits occurred at weekly intervals for a three-
week period. During the baseline visit, demographic and
HIV and other medical history data was collected includ-
ing concurrent medications, validated questionnaires
pertaining to antiretroviral adherence [31] and symptom
distress [32] were completed, weight was measured and
blood work to assess laboratory values was drawn.
Pharmacokinetic analysis
At each of the three visits, patients had a pre-dose (Cmin)
and a maximum (Cmax) PI or NNRTI drug level drawn.
Patients were asked to fast from midnight of the previ-
ous night. One hour before their scheduled morning
dose the pre-dose blood collection was drawn (Cmin t)
(alternative arrangements were made if the patient took
her drugs in the evening). Following the pre-dose blood
collection, patients consumed a standard breakfast
(consisting of 50% carbohydrate, 30% fat, 20% protein)
after which time the morning antiretroviral dose was ad-
ministered. Cmax levels were drawn at 2 hours post-dose
for atazanavir 400 mg QD [33], 3 hours post-dose for
atazanavir/ritonavir 300/100 mg QD [33], 4 hours post-
dose for lopinavir/ritonavir 400/100 mg BID [34], 5
hours post-dose for efavirenz 600 mg QD [35], and 2
hours post-dose for nevirapine (both 200 mg BID and
400 mg QD [36]). The plasma drug level samples were
all stored in cryovials at −20°C or lower and shipped for
concurrent assessment at the end of the study. Concen-
trations of the PIs and the NNRTIs in plasma were mea-
sured simultaneously by sensitive and selective, validated
high-performance liquid chromatography coupled to
tandem mass-spectroscopy (LC-MS/MS) [37]. All sam-
ples were analyzed at the pharmacokinetic laboratory at
the Ottawa Hospital Research Institute in Ottawa,
Canada.
The PK endpoints for each patient were determined
by taking the median of the three weekly values for the
Cmin and Cmax. The rationale for measuring drug levels
at three separate time points was that there is potentially
intra-individual variability in drug levels, especially for
PIs [38,39]. Using the median value for the endpoints
eliminated outliers. The three drug level measurements
allowed for the calculation of intra-patient variability.
Statistical analyses
Baseline characteristics of the study population were
summarized using medians and interquartile ranges
(IQR) for continuous variables and frequencies and pro-
portions for categorical variables.
The mean Cmin and Cmax drug levels in the historical
HIV population were taken from the most recent prod-
uct monograph when possible, or from a published study
if the product monograph did not report these values
[33-36]. Next, for each subject the ratio of their median
Cmin and Cmax for their main PI or NNRTI to this pub-
lished drug level was calculated and used as the primary
outcome as previously reported by Burger et al. [40] Due
to the lack of published population PK data for ritonavir
when included as part of regimen in a “boosting” role,
we only calculated the ratios for the main PI in a partici-
pant’s regimen. Differences between the Cmin ratio and
Cmax ratio to the population mean were conducted using
a Wilcoxon sign-rank test for a median of 1. For com-
parison purposes, PK levels were dichotomized into high
and low levels with a high level defined as ≥ 1.5 X
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arithmetic population mean of the Cmin and Cmax for
each drug. Inter-patient variability of Cmin and Cmax for
each antiretroviral drug was assessed by calculating the
coefficient of variation (CV) using each individual’s me-
dian Cmin and Cmax. An intra-patient CV for each par-
ticipant was calculated from the Cmin and Cmax values
obtained at each of the 3 visits. These values are summa-
rized using median and IQR of the individual CVs. The
inter-patient CV is a measure of variation among indi-
viduals whereas intra-patient CV measures variation
within an individual The inter-patient CV is calculated
as the ratio of the standard deviation to the mean X 100;
the higher the value, the more variability exists. Finally,
linear regression models were fit to assess correlates of
the square root-transformed Cmin and Cmax ratios. The
square-root transformation was used because the un-
transformed Cmin and Cmax ratios were both right-
skewed. The regression models included indicator vari-
ables to account for the different antiretroviral medica-
tions and each potential correlate was included
separately in an adjusted model. Statistical analyses were




Ninety women were enrolled from 14 sites across
Canada between 2/2007 and 11/2008. Eight women were
excluded for the following reasons: one due to missing
data, six were not on a current cART regimen deemed
eligible to be included in this analysis, and one because
she was not on standard dosing schedule. The data is
summarized for the remaining 82 patients. Median age
of the study population was 41 years (IQR 36–48) and
56% identified as Black. The median times since their
HIV diagnosis and start of their current cART regimen
were 7 years (IQR 3–11) and 20 months (IQR 9–45), re-
spectively. Fifty-seven percent were taking a PI-
containing regimen (81% being ritonavir-boosted and
19% unboosted) and 43% a NNRTI-containing regimen.
All participants had an undetectable viral load with a
median CD4+ count at the time of enrolment of 487
cells/μL (IQR 380–621). Additional demographic and
clinical variables of the study population are summarized
in Table 1. No relevant concurrent medications were be-
ing taken by the participants.
Drug level ratios by antiretroviral drug
The Cmin and Cmax summaries and historical values used
to calculate the ratios are reported in Table 2 [33-36].
Paired values for the Cmin and Cmax data for each dosing
regime are shown in Figure 1. Overall, the median ratio
of the participants’ Cmin to historical mean values was
1.21 (IQR 0.72-1.89, p=0.003) and the median ratio of
Cmax to historical mean values was 0.82 (IQR 0.59-1.14,
p=0.004). Twenty-eight participants (34%) had Cmin ≥
1.5 X arithmetic population mean of the Cmin for each
drug and seven participants (9%) had Cmax ≥ 1.5 X arith-
metic population mean of the Cmax for each drug; all on
an NNRTI. The median ratios of Cmin and Cmax to his-
torical mean values for each specific antiretroviral drug
overall and for each dose are presented in Table 3.
Intra-patient and inter-patient variability of antiretroviral
drug levels
The intra- and inter-patient variability of each antiretro-
viral drug’s Cmin and Cmax was assessed using CV; data








Injection drug use 11 (13%)
Endemic country 27 (33%)
Heterosexual contact 59 (72%)
Blood transfusion 7 (9%)
Unknown 8 (10%)
Years since HIV diagnosis 7 (3–11)
CD4+ cell count prior to cART (μL) 232 (128–400)
Current CD4+ cell count (μL) 487 (380–621)
VL prior to cART (log10 copies/mL) 4.5 (3.0-5.0)
AIDS diagnosis 19 (23%)
Months since start of cART 20 (9–45)
cART includes PI 47 (57%)
cART includes NNRTI 35 (43%)
Missed ARV dose in past week 6 (7%)
Hepatitis B co-infection 2 (2%)
Hepatitis C co-infection 10 (12%)
Weight (kg) 67.3 (60.3-81.5)
BMI 25.8 (22.4-31.3)
Menstrual status
Regular periods 44 (54%)
Irregular periods 10 (12%)
Current amenorrhea 9 (11%)
Menopausal 19 (23%)
Continuous variables presented as medians with interquartile range;
categorical variables presented as n (%).VL, viral load; AIDS, acquired
immunodeficiency syndrome; cART, combination antiretroviral therapy; PI,
protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; ARV,
antiretroviral; BMI, body mass index.
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are presented in Table 4. Data from 2 participants for
whom PK samples were only obtained at one visit were
excluded from the intra-patient variability calculations.
Nevirapine BID and lopinavir/ritonavir BID showed the
least inter-patient variability with the lowest CVs for
both Cmin and Cmax. Nevirapine BID and efavirenz had
the lowest intra-patient variability variability for Cmin,
while nevirapine BID, lopinavir/ritonavir BID, and
efavirenz demonstrated lowest intra-patient variability
for Cmax. Inter- and intra- patient variability was
high for atazanavir, particularly when not boosted with
ritonavir.
Linear regression models for antiretroviral Cmin and Cmax
Linear regression models to assess the relationship be-
tween the square root-transformed Cmin ratio and demo-
graphic and clinical variables of the population were
carried out (Table 5). Higher CD4+ cell count was the
only variable significantly associated with higher Cmin ra-
tios (Beta coefficient=0.04/ 100 cells per μL increase,
Table 2 Reference population mean and Study Participants Cmin and Cmax by antiretroviral drug
Cmin Cmax








Atazanavir** [33] 400 QD 9 273 214 (95–373) 3152 1870 (979–2950)
Atazanavir** boosted with ritonavir [33] 300 QD 18 862 835 (663–1220) 5233 3430 (2670–4450)
Lopinavir boosted with ritonavir [34] 400 BID 16 5500 6660 (4360–7710) 9800 8420 (7240–11600)
Lopinavir boosted with ritonavir [34] 800 QD 4 1700 6445 (2452–8260) 11800 11685 (7403–14900)
Efavirenz [35] 600 QD 16 1768 1680 (1180–3450) 4072 3235 (2330–5180)
Nevirapine [36] 200 BID 11 3730 5270 (3380–7190) 5740 5510 (4810–7860)
Nevirapine [36] 400 QD 8 2880 5995 (2590–7275) 6690 6400 (4838–9380)
QD, once daily; BID, twice daily; IQR, interquartile range.
*Nucleos(t)ide backbone: of 9 participants on Atazanavir 400 mg QD, all 9 were taking Abacavir/3TC; of 18 participants on Atazanavir/ritonavir 300 mg/100 mg
QD, 11 were taking Abacavir/3TC, 3 Tenofivir/FTC, 3 Tenofivir/3TC and 1 Zidovudine/3TC; of 16 participants on Lopinavir/ritonavir 400 mg/100 mg BID, 7 were
taking Zidovudine/3TC, 6 Abacavir/3TC, 1 Tenofivir/FTC, 1 Tenofivir/3TC and 1 was on PI monotherapy; of 4 participants on Lopinavir/ritonavir 800 mg/200 mg QD,
2 were taking Tenofivir/FTC, 1 Abacavir/3TC, 1 Didanosine/3TC; of 16 participants on Efavirenz 600 mg QD, 5 were taking Tenofivir/FTC, 5 Abacavir/3TC, 5
Zidovudine/3TC, 1 Tenofovir/3TC; of 11 participants on Nevirapine 200 mg BID, 7 were taking Zidovudine/3TC, 4 Abacavir/3TC; of 8 participants on Nevirapine 400
mg/ QD, 4 were taking Abacavir/3TC, 1 Tenofivir/FTC, 1 Zidovudine/3TC, 1 Tenofivir/3TC, 1 Didanosine/3TC.
** Of the 27 particpants taking Atazanavir or Atazanvir/ritonavir, none were taking any gastric acid suppression medication.
Figure 1 Paired Cmin and Cmax values for each participant by antiretroviral drug and dose. The Cmin values are identified by circles and the
Cmax values by triangles. The reported population mean Cmin and Cmax values for each antiretroviral drug and dose are presented with the
hatched lines (−−−).
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95% CI=0.003-0.080; p=0.03). Similar analyses were car-
ried out for the assessment of the correlates of the
square root-transformed Cmax ratios and only injection
drug use showed a trend to be negatively associated with
Cmax ratio (Beta coefficient=−0.10, 95% CI=−0.23-0.02;
p=0.10).
Discussion
In this cross-sectional study of 82 HIV-positive women
taking cART with full virologic suppression, median pre-
dose drug levels were found to be significantly higher
than historical controls. Approximately one- third of
women had a Cmin value more than 1.5 times higher
than historical control values. Since the majority of his-
torical controls consist of men, this finding supports the
growing literature indicating that drug levels are higher
in women than in men.
Our findings also support the increasing body of litera-
ture on the gender differences in drug disposition and
PK of all drugs. However, in the HIV population, these
differences may in part be due to race as many of the
historical controlled participants were White men, and
as in our study, many of the females infected with HIV
globally are Black. Several studies have investigated the
relationship of antiretroviral PK with genetically deter-
mined factors that might differ by individual ancestral
history [41-45]. Racial differences have been found in P-
glycoprotein (PGP) activity, an efflux protein which
pumps its substrates, including the PIs, out of cells, away
from their site of action. For example, Africans are four
times more likely than white Americans or Japanese in-
dividuals to have the CC genotype at position 3435 of
the gene coding for PGP [45]. Fellay and colleagues [41]
demonstrated that persons with the CC genotype have
higher PGP-activity, higher serum drug levels. Similarly,
there are racial differences in the prevalence of slow-
metabolizers of specific pathways, for example 2D6 and
2B6, of the cytochrome P-450 system of drug metabol-
ism in the liver [43]. Thus, there may be genetically de-
termined heterogeneity in the in vivo transport and
metabolism of antiretroviral agents, resulting in variation
in serum and intracellular drug levels.
Table 3 Ratio of Cmin and Cmax values to Historical Population Means by antiretroviral drug and dose
Cmin Cmax











Median ratio ( IQR)
p-valuea
All 82 28 (34.1%) 1.21 (0.72-1.89) <.01 7 (8.5%) 0.82 (0.59-1.14) <.01
Atazanavir 400 QD 9 2 (22.2%) 0.78 (0.35-1.37) 0.71 0 (0.0%) 0.59 (0.31-0.94) 0.04
Atazanavir (boosted with ritonavir) 300 QD 18 4 (22.2%) 0.97 (0.77-1.42) 0.58 0 (0.0%) 0.66 (0.51-0.85) <.001
All Atazanavir 27 6 (22.2%) 0.95 (0.53-1.42) 0.76 0 (0.0%) 0.65 (0.44-0.87) <.0001
Lopinavir (boosted with ritonavir) 400 BID 16 3 (18.8%) 1.21 (0.79-1.40) 0.27 0 (0.0%) 0.86 (0.74-1.18) 0.32
Lopinavir (boosted with ritonavir) 800 QD 4 3 (75.0%) 3.79 (1.44-4.86) 0.25 0 (0.0%) 0.99 (0.63-1.26) 0.63
All Lopinavir 20 6 (30.0%) 1.22 (0.79-1.81) 0.11 0 (0.0%) 0.86 (0.72-1.21) 0.29
Efavirenz 600 DQ 16 6 (37.5%) 0.95 (0.67-1.95) 0.37 4 (25.0%) 0.79 (0.57-1.27) 0.63
Nevirapine 200 BID 11 5 (45.5%) 1.41 (0.91-1.93) 0.03 2 (18.2%) 0.96 (0.84-1.37) 0.46
Nevirapine 400 QD 8 5 (62.5%) 2.08 (0.90-2.53) 0.08 1 (12.5%) 0.96 (0.72-1.40) 0.95
All Nevirapine 19 10 (52.6%) 1.62 (0.91-2.32) <0.01 3 (15.8%) 0.96 (0.81-1.37) 0.47
IQR, Interquartile range. a Sign rank test for a median ratio different than 1.
Table 4 Inter-patient and Intra-patient variability of Cmin and Cmax for each antiretroviral agent
Cmin Cmax
Antiretroviral agent n Mean (SD) Inter-patient CV Intra-patient CV
median (IQR)
Mean (SD) Inter-patient CV Intra-patient CV
median (IQR)
Atazanavir 400 QD 9 250.4 (195.4) 78.0% 57.4 (40.5-86.7) 2000.4 (1145.5) 57.3% 61.9 (44.2-66.0)
Atazanavir (boosted with ritonavir) 300 QD 18 1065.6 (699.2) 65.6% 26.3 (15.6-56.1) 3525.3 (1459.1) 41.4% 32.7 (17.2-54.5)
Lopinavir (boosted with ritonavir) 400 BID 16 6370.0 (2846.4) 44.7% 23.8 (12.8-75.8) 8991.3 (2953.3) 32.8% 14.0 (12.3-21.7)
Lopinavir (boosted with ritonavir) 800 QD 4 5356.2 (3882.3) 72.5% 63.4 (35.2- 115) 11151.3 (4433.2) 39.8% 15.6 ( 7.4-28.4)
Efavirenz 600 QD 16 2196.9 (1209.2) 55.0% 17.7 (10.5-25.1) 3929.4 (2060.6) 52.4% 15.5 (12.8-27.9)
Nevirapine 200 BID 11 5693.6 (2586.8) 45.4% 13.9 (10.2-27.8) 6490.9 (2454.9) 37.8% 10.7 ( 7.8-19.6)
Nevirapine 400 QD 8 5027.9 (2867.2) 57.0% 21.3 (12.1-44.9) 6924.4 (2761.1) 39.9% 22.8 ( 8.3-53.8)
SD, Standard deviation; CV, Coefficient of Variation; IQR, Interquartile Range.
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A number of other studies have assessed the gender
differences in antiretroviral PK, particularly of the older
PIs. In a study of 186 patients (15.6% female), Fletcher
and colleagues [23] demonstrated that serum levels of
saquinavir were significantly higher in women than in
men, independent of body size. Another study sought to
characterize the PK of saquinavir (1000 mg BID),
lopinavir (400 mg BID), and ritonavir (100 mg BID) in a
multidrug rescue therapy study [24]. Twenty-five pa-
tients (28% women) were included in the study group
and fifteen (20% women) were included in the compari-
son group that did not receive saquinavir. Area under
the curve (AUC), Cmax, and Cmin values for saquinavir
and ritonavir were significantly higher in women than in
men, though there were no significant differences in
weight or body mass indexes between genders. Work by
Dickinson and colleagues, who looked at the PK of saquin-
avir and ritonavir in 34 patients on this combination,
showed that in women a higher exposure to saquinavir
might, at least in part, be driven by higher exposure to ri-
tonavir [25]. Pharmacokinetic studies of newer PIs have
only been reported in product monographs limited to data
showing that women have modest increases in AUC of ap-
proximately 20% for lopinavir, atazanavir and darunavir
[33,34,46]. In terms of NNRTIs, investigators have demon-
strated higher serum efavirenz and nevirapine levels in
women [26-29]. A previous report using a full 12 hour PK
of nevirapine showed a gender difference of an 18.9%
Table 5 Linear regression models for square-root transformed Cmin and Cmax
Cmin Cmax
Variables Beta 95% CI p-value Beta 95% CI p-value
Age (per 10 years) 0.02 (−0.07 - 0.11) 0.62 0.00 (−0.04 - 0.05) 0.95
Race
White Reference
Black −0.16 (−0.35 - 0.03) 0.09 −0.06 (−0.16 - 0.04) 0.25
Other −0.20 (−0.50 - 0.11) 0.20 0.01 (−0.15 - 0.17) 0.91
Risk Factor
IDU −0.21 (−0.45 - 0.04) 0.10 −0.10 (−0.23 - 0.02) 0.10
Endemic country −0.08 (−0.26 - 0.10) 0.38 −0.07 (−0.16 - 0.02) 0.14
Heterosexual contact 0.13 (−0.05 - 0.32) 0.16 0.07 (−0.03 - 0.16) 0.16
Blood transfusion −0.08 (−0.38 - 0.22) 0.60 −0.08 (−0.23 - 0.07) 0.31
Unknown −0.06 (−0.34 - 0.23) 0.69 0.01 (−0.14 - 0.15) 0.90
Years since HIV diagnosis (per 10 years) 0.00 (−0.00 - 0.00) 0.84 −0.00 (−0.00 - 0.00) 0.53
Baseline CD4 (per 100/μL) 0.02 (−0.02 - 0.06) 0.28 0.00 (−0.02 - 0.02) 0.97
Baseline CD4 > 200/μL 0.07 (−0.11 - 0.24) 0.46 0.03 (−0.06 - 0.12) 0.51
Current CD4 (per 100/μL) 0.04 ( 0.00 - 0.08) 0.03 0.01 (−0.01 - 0.03) 0.61
Current CD4 > 200/μL 0.30 (−0.25 - 0.84) 0.28 0.16 (−0.12 - 0.44) 0.26
Baseline VL (log10 copies/mL) −0.02 (−0.09 - 0.06) 0.64 −0.00 (−0.04 - 0.03) 0.81
AIDS diagnosis 0.07 (−0.12 - 0.27) 0.46 0.06 (−0.04 - 0.16) 0.27
Years on current regimen −0.01 (−0.05 - 0.03) 0.68 −0.00 (−0.02 - 0.02) 0.83
Hepatitis B co-infection 0.22 (−0.34 - 0.78) 0.44 −0.04 (−0.33 - 0.24) 0.76
Hepatitis C co-infection 0.18 (−0.07 - 0.44) 0.17 −0.10 (−0.23 - 0.03) 0.14
Smoking Status
Smoker Reference
Previous Smoker 0.02 (−0.27 - 0.31) 0.89 0.05 (−0.10 - 0.20) 0.49
Never −0.13 (−0.31 - 0.06) 0.18 0.02 (−0.08 - 0.11) 0.70
Hypertension 0.14 (−0.12 - 0.41) 0.28 0.02 (−0.12 - 0.15) 0.82
Diabetes 0.02 (−0.43 - 0.47) 0.94 −0.05 (−0.28 - 0.18) 0.66
Weight (per kg) 0.00 (−0.00 - 0.01) 0.36 0.00 (−0.00 - 0.00) 0.32
BMI (per kg/m2) 0.00 (−0.01 - 0.02) 0.47 0.00 (−0.00 - 0.01) 0.64
Menopausal (self-reported) 0.05 (−0.14 - 0.25) 0.59 0.03 (−0.07 - 0.14) 0.55
IDU, injection drug use; VL, viral load; AIDS, acquired immunodeficiency syndrome; BMI, body mass index.
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lower AUC in males when corrected for body weight [26].
In the same study, pregnant women had lower nevirapine
exposure and this effect did not seem to be driven by body
weight.
Our data also adds to the literature on gender differ-
ences in Cmax of current antiretroviral agents. These ob-
servations should be interpreted with caution as the
collection of Cmax samples in this study was done at a
single standardized timepoint; therefore, if the Cmax
sampling time was slightly off from the real Tmax then
the resulting Cmax observations would be interpreted as
lower. In our study, atazanavir had the lowest ratios of
both Cmin and Cmax versus historical reference values,
but also the greatest observed inter-patient variability. In
general, a higher degree of variability was noted for Cmin
as compared to Cmax values.
Few studies have assessed intra-patient variability of
antiretroviral drug levels for either gender. Over our 3-
week sampling period, we found higher intra-patient
variability in the PI-based regimens compared to the
NNRTIs; a similar finding to the retrospective summary
provided by Fabbiani and colleagues [47]. More specific-
ally, unboosted atazanavir had the highest intra- and
inter-patient CVs for Cmin and Cmax, whereas efavirenz
and nevirapine had the lowest CVs for intra-patient vari-
ability. This most likely reflects the longer half-life for
both nevirapine and efavirenz, compared to PIs. Despite
ritonavir boosting for both, the intra-patient variability
for lopinavir Cmax was substantially lower than that of
atazanavir, which may reflect the absence of a food and
gastric pH effects on lopinavir absorption as compared
to atazanavir absorption. In addition, lopinavir is co-
formulated with ritonavir, thus ensuring simultaneous
coadministration of both drugs, whereas atazanavir ab-
sorption may be impacted if ritonavir is not taken at the
same time for reasons such as patient choice (e.g., con-
cerns of selective side effects of ritonavir) or forgetful-
ness since ritonavir capsules require refrigeration. In our
study, inter-patient CV for Cmin and Cmax of boosted
and unboosted atazanavir appeared to be lower than his-
torical values from predominantly male populations,
while intrapatient CV for Cmin of unboosted atazanavir
appeared to be higher than historical data. For NNRTIs,
observed intra- and inter-patient Cmin CVs of efavirenz
and nevirapine appeared to be lower than historical con-
trols. As such, the existence of sex-based differences in
antiretroviral variability cannot be ruled out.
Correlates of antiretroviral drug levels in women have
only been investigated by few studies. Gibbons and col-
leagues examined the potential for age-dependent
changes in lopinavir and efavirenz levels in female sub-
jects in a retrospective analysis of therapeutic drug mon-
itoring on non-pregnant women receiving either
lopinavir/ritonavir 400 mg /100 mg twice daily or
efavirenz 600 mg daily [48]. They found that women >
50 years of age had significantly higher 8–16 hour
efavirenz levels when compared to women < 40 years of
age (p=0.046). In our study, we found that Cmin ratio in-
creased with CD4+ cell count and there was some indi-
cation that it was lower among injection drug users.
There were no statistically significant correlates of Cmax.
Of note, there was no correlation between drug levels
and body weight or body mass index. The lack of statis-
tical significance may be related to the attempts to make
our population homogenous.
Our study has a number of limitations, most notably
the lack of a concurrent male control group which
would have allowed real-time assessment of sex differ-
ences in drug levels. The fact that historical control data
was used results in the inability to report on the demo-
graphics of the controls including the true proportion of
cases that were male, ethnicity, weight, and co-infection
status. The restriction of our study to women on their
first cART regimen with virologic suppression to ensure
homogeneity likely contributed to the lack of range
amongst our covariates, decreasing our ability to detect
differences and associations. If higher concentrations
were associated with toxicity, then the women may have
switched off the regimen or been inconsistently adherent
and experienced viral failure and would not have been
eligible for this data set. The demand and time commit-
ment for the participants was high and likely led to some
degree of selection bias of women who are committed to
therapy and research. Also, there were small sample
sizes for each drug dosing (e.g. only 4 participations tak-
ing lopinavir/ritonavir 800 mg/100 mg OD and 8 taking
nevirapine 400 mg OD) and for this reason it was diffi-
cult to make conclusions regarding specific drugs and
drug dosing.
Conclusion
In summary, our data adds to the growing literature on
the gender differences of antiretroviral drug levels. Our
study showed that the PIs and NNRTIs overall Cmin ra-
tios were significantly higher in our HIV-positive female
participants as compared to men (historical controls). In
particular, we observed the highest Cmin for nevirapine
and lopinavir. These latter observations add to the litera-
ture by providing data on newer antiretroviral agents,
and could explain nevirapine’s important gender-specific
drug toxicity. Our study was also able to study intra-
and inter-patient variability for PIs and NNRTIs Cmin ra-
tios and found significant variability particularly for
unboosted and boosted atazanavir. This intra-patient
variability could have clinical implications with respect
to toxicity and efficacy. These findings require further
study to elucidate the mechanism and clinical conse-
quences of these differences and results. It also
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emphasizes the importance of gender-specific analyses
when investigating antiretroviral efficacy and toxicity.
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